{"id":6211,"date":"2025-05-07T17:03:55","date_gmt":"2025-05-07T17:03:55","guid":{"rendered":"https:\/\/www.retinaconsultant.com\/?p=6211"},"modified":"2025-05-07T17:38:44","modified_gmt":"2025-05-07T17:38:44","slug":"phase-2-better-trial-results-shared-at-arvo-2025","status":"publish","type":"post","link":"https:\/\/www.retinaconsultant.com\/?p=6211","title":{"rendered":"Phase 2 BETTER trial results shared at ARVO 2025"},"content":{"rendered":"<h5 class=\"p1\"><span class=\"s1\"><strong><a href=\"https:\/\/www.ophthalmologytimes.com\/view\/phase-2-better-trial-results-shared-at-arvo-2025\" style=\"font-weight: 600;letter-spacing: 0.4pt;text-decoration: underline;\">Click here<\/a> <\/strong>to view the original post by<strong> <a href=\"https:\/\/www.ophthalmologytimes.com\/news\" style=\"font-weight: 600;letter-spacing: 0.4pt;text-decoration: underline;\">Ophthalmology Times<\/a>.<\/strong><\/span><\/h5>\n<p><\/p>\n<p class=\"p1\"><em><span class=\"s1\">In addition to our own original articles, the <a href=\"\/\">Retina Consultant<\/a> team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina &amp; <\/span><span class=\"s1\">ophthalmology landscape,\u00a0<\/span><span class=\"s1\">Full credit <\/span><span class=\"s1\">belongs to the original authors and publication.\u00a0 <\/span><\/em><\/p>\n<p><\/p>\n<p class=\"p1\"><em><span class=\"s1\">By clicking the link above, you will be leaving our site to view an article from its original source.<\/span><\/em><!-- wp:separator {\"className\":\"is-style-wide\",\"style\":{\"color\":{\"background\":\"#eaeaea\"}}} --><\/p>\n<p><\/p>\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background is-style-wide\" style=\"background-color: #eaeaea; color: #eaeaea;\" \/>\n<p><strong>Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.<\/strong><style id=\"wpforms-css-vars-7217\">\n\t\t\t\t#wpforms-7217 {\n\t\t\t\t\n\t\t\t}\n\t\t\t<\/style><div class=\"wpforms-container wpforms-container-full wpforms-render-modern\" id=\"wpforms-7217\"><form id=\"wpforms-form-7217\" class=\"wpforms-validate wpforms-form wpforms-ajax-form\" data-formid=\"7217\" method=\"post\" enctype=\"multipart\/form-data\" action=\"\/index.php?rest_route=%2Fwp%2Fv2%2Fposts%2F6211\" data-token=\"0e42c12f4a0ff54957401c5e999dbf3b\" data-token-time=\"1775362322\"><noscript class=\"wpforms-error-noscript\">Please enable JavaScript in your browser to complete this form.<\/noscript><div id=\"wpforms-error-noscript\" style=\"display: none;\">Please enable JavaScript in your browser to complete this form.<\/div><div class=\"wpforms-field-container\">\t\t<div id=\"wpforms-7217-field_1-container\"\n\t\t\tclass=\"wpforms-field wpforms-field-text\"\n\t\t\tdata-field-type=\"text\"\n\t\t\tdata-field-id=\"1\"\n\t\t\t>\n\t\t\t<label class=\"wpforms-field-label\" for=\"wpforms-7217-field_1\" >Email<\/label>\n\t\t\t<input type=\"text\" id=\"wpforms-7217-field_1\" class=\"wpforms-field-medium\" name=\"wpforms[fields][1]\" >\n\t\t<\/div>\n\t\t<div id=\"wpforms-7217-field_2-container\" class=\"wpforms-field wpforms-field-email\" data-field-id=\"2\"><label class=\"wpforms-field-label wpforms-label-hide\" for=\"wpforms-7217-field_2\" aria-hidden=\"false\">Email <span class=\"wpforms-required-label\" aria-hidden=\"true\">*<\/span><\/label><input type=\"email\" id=\"wpforms-7217-field_2\" class=\"wpforms-field-large wpforms-field-required\" name=\"wpforms[fields][2]\" placeholder=\"Email address\" spellcheck=\"false\" aria-errormessage=\"wpforms-7217-field_2-error\" required><\/div><script>\n\t\t\t\t( function() {\n\t\t\t\t\tconst style = document.createElement( 'style' );\n\t\t\t\t\tstyle.appendChild( document.createTextNode( '#wpforms-7217-field_1-container { position: absolute !important; overflow: hidden !important; display: inline !important; height: 1px !important; width: 1px !important; z-index: -1000 !important; padding: 0 !important; } #wpforms-7217-field_1-container input { visibility: hidden; } #wpforms-conversational-form-page #wpforms-7217-field_1-container label { counter-increment: none; }' ) );\n\t\t\t\t\tdocument.head.appendChild( style );\n\t\t\t\t\tdocument.currentScript?.remove();\n\t\t\t\t} )();\n\t\t\t<\/script><\/div><!-- .wpforms-field-container --><div class=\"wpforms-submit-container\" ><input type=\"hidden\" name=\"wpforms[id]\" value=\"7217\"><input type=\"hidden\" name=\"page_title\" value=\"\"><input type=\"hidden\" name=\"page_url\" value=\"https:\/\/www.retinaconsultant.com\/index.php?rest_route=\/wp\/v2\/posts\/6211\"><input type=\"hidden\" name=\"url_referer\" value=\"\"><button type=\"submit\" name=\"wpforms[submit]\" id=\"wpforms-submit-7217\" class=\"wpforms-submit newsletter-form\" data-alt-text=\"Sending...\" data-submit-text=\"Sign Up\" aria-live=\"assertive\" value=\"wpforms-submit\">Sign Up<\/button><img src=\"https:\/\/www.retinaconsultant.com\/wp-content\/plugins\/wpforms-lite\/assets\/images\/submit-spin.svg\" class=\"wpforms-submit-spinner\" style=\"display: none;\" width=\"26\" height=\"26\" alt=\"Loading\"><\/div><\/form><\/div>  <!-- .wpforms-container --><\/p>\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background is-style-wide\" style=\"background-color: #eaeaea; color: #eaeaea;\" \/>\n<div class>\n<div class=\" figure\">\n<div class=\"top-[-100%] block w-[1px] transition-opacity duration-500 ease-in-out opacity-0 overflow-hidden\"><img decoding=\"async\" class=\"m-auto absolute inset-0 max-w-[0%] max-h-[0%] border-[3px] border-solid border-white shadow-[0px_0px_8px_rgba(0,0,0,0.3)] box-border transition ease-in-out duration-500\" src=\"https:\/\/www.retinaconsultant.com\/wp-content\/uploads\/2025\/05\/45b20878714976c8ac2254a6ad7723a62d17f0bb-1200x674-1.jpg\" \/><\/div>\n<\/div>\n<\/div>\n<p class=\"pb-2\">Isarna Therapeutics shared final positive results from the Phase 2 BETTER trial, which evaluated the candidate ISTH0036 to address retinal fibrosis. ISTH0036 is an investigational antisense oligonucleotide designed to selectively suppress the production of transforming growth factor beta 2 (TGF-\u03b22), a key cytokine involved in fibrosis and disease progression in retinal pathologies.<sup class=\"text-inherit\">1<\/sup><\/p>\n<p class=\"pb-2\">This data was presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on May 6, 2025 by Isarna\u2019s Chief Medical Officer, Prof. Marion R. Munk.<\/p>\n<p class=\"pb-2\">The BETTER study evaluated ISTH0036 in both treatment-na\u00efve and anti-VEGF\u2013pretreated but inactive patients across sites in Austria and India. Patients received intravitreal injections of ISTH0036 every eight weeks (Q8W). These patients experienced stable or improved best-corrected visual acuity (BCVA), along with meaningful anatomical improvements in the retina. All patient groups showed a reduction in central retinal thickness (CRT).<sup class=\"text-inherit\">1<\/sup><\/p>\n<p class=\"pb-2\">The company noted<sup class=\"text-inherit\">1<\/sup> that eyes with nAMD and fibrosis-associated hyperreflective material (HRM) exhibited a significant decrease in HRM volume following ISTH0036 treatment, contrasting sharply with increases seen in fellow eyes receiving standard anti-VEGF therapy. In DME patients, ISTH0036 reduced intraretinal fluid volume in treatment-na\u00efve and previously anti-VEGF\u2013treated eyes. Intraocular pressure remained, and the treatment was well tolerated.<\/p>\n<p class=\"pb-2\">In addition to presenting this data at the ARVO 2025 meeting in Salt Lake City, Utah, Prof. Marion R. Munk, CMO of Isarna Therapeutics is also quoted in the company\u2019s press release<sup class=\"text-inherit\">1<\/sup> on this news, saying, \u201cThe results from the BETTER trial underscore the potential of ISTH0036 as a first-in-class antifibrotic agent that directly targets TGF\u2013\u03b22\u2013driven fibrosis\u2014a key driver of disease progression in nAMD and DME. This is a promising advance toward transforming care for patients facing progressive vision loss despite optimal standard therapy. Isarna\u2019s next step will be to discuss the results and our development strategy with regulators in the US and EU to move ISTH0036 into Phase 2b\/ Phase 3 pivotal clinical studies.\u201d<\/p>\n<h6 class=\"text-sm pb-4 pt-2\">Reference:<\/h6>\n<h6 class=\"text-sm pb-4 pt-2\">1. Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Results at ARVO 2025. Isarna Therapeutics. May 7, 2025. Accessed May 7, 2025. <a rel=\"nofollow\" target=\"_self\" href=\"https:\/\/www.streetinsider.com\/Globe+Newswire\/Isarna+Therapeutics+Presents+Positive+Phase+2+BETTER+Trial+Final+Results+at+ARVO+2025\/24752465.html\">https:\/\/www.streetinsider.com\/Globe+Newswire\/Isarna+Therapeutics+Presents+Positive+Phase+2+BETTER+Trial+Final+Results+at+ARVO+2025\/24752465.html<\/a><\/h6>\n","protected":false},"excerpt":{"rendered":"<p>Click here to view the original post by Ophthalmology Times. In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina &amp; ophthalmology landscape,\u00a0Full credit belongs to the original authors and publication.\u00a0 By clicking the link [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6212,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"categories":[17],"tags":[],"class_list":{"0":"post-6211","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ophthalmology-times","8":"entry"},"featured_image_src":"https:\/\/www.retinaconsultant.com\/wp-content\/uploads\/2025\/05\/45b20878714976c8ac2254a6ad7723a62d17f0bb-1200x674-1-600x400.jpg","featured_image_src_square":"https:\/\/www.retinaconsultant.com\/wp-content\/uploads\/2025\/05\/45b20878714976c8ac2254a6ad7723a62d17f0bb-1200x674-1-600x600.jpg","author_info":{"display_name":"Retina News Feed","author_link":"https:\/\/www.retinaconsultant.com\/?author=1"},"_links":{"self":[{"href":"https:\/\/www.retinaconsultant.com\/index.php?rest_route=\/wp\/v2\/posts\/6211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.retinaconsultant.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.retinaconsultant.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.retinaconsultant.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.retinaconsultant.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6211"}],"version-history":[{"count":0,"href":"https:\/\/www.retinaconsultant.com\/index.php?rest_route=\/wp\/v2\/posts\/6211\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.retinaconsultant.com\/index.php?rest_route=\/wp\/v2\/media\/6212"}],"wp:attachment":[{"href":"https:\/\/www.retinaconsultant.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6211"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.retinaconsultant.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6211"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.retinaconsultant.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}